Home Blog International Addiction Treatment Referrals: A Guide for U.S. Healthcare Professionals

International Addiction Treatment Referrals: A Guide for U.S. Healthcare Professionals

This article is intended for general professional education and is not legal, regulatory, or patient-specific medical advice. U.S. healthcare professionals should follow applicable federal and state law, organizational policy, licensing requirements, HIPAA, 42 CFR Part 2 when applicable, and their own compliance guidance when making referrals or sharing records. Patients with acute medical or psychiatric instability should receive appropriate local emergency or stabilization care before international travel is considered.

International addiction treatment referrals require more than identifying an available residential bed. For U.S. healthcare professionals, a cross-border referral should establish clinical fit, medical stability, receiving-program quality, patient consent, appropriate information transfer, travel feasibility, and a clear plan for continuing care when the patient returns home.

When those elements are handled systematically, international treatment can be considered as one option within the broader continuum of addiction care. The referral should be patient-centered and clinically defensible, with the same scrutiny a clinician would apply to an interstate residential placement in the United States – plus additional attention to jurisdiction, travel, language, and continuity across borders.

START WITH LEVEL OF CARE, NOT DESTINATION

The first referral question is not “Which country?” It is “What level of care does this patient need?” The ASAM Criteria uses a multidimensional assessment framework that considers intoxication and withdrawal risk, biomedical conditions, psychiatric and cognitive conditions, substance use-related risk, the recovery environment, and person-centered considerations.

That framework is useful even when the receiving program is outside the United States because it keeps the referral anchored to clinical need. A patient who requires hospital-level medical management should not be sent directly to a residential program that cannot provide it simply because a bed is available.

Likewise, a patient who is medically stable but needs a structured residential environment, integrated psychiatric support, relapse-prevention work, and a temporary separation from a high-risk recovery environment may be a reasonable candidate for residential treatment abroad if the receiving facility can meet those needs.

WHEN AN INTERNATIONAL REFERRAL MAY BE CONSIDERED

An international residential referral may be reasonable when several conditions align:

The patient meets clinical indications for residential care and is medically stable enough to travel.
The receiving program can manage the patient’s withdrawal, medical, psychiatric, medication, and behavioral needs.
The patient understands the international setting and voluntarily agrees to the plan.
The program offers a meaningful access, cost, privacy, environmental, or treatment-fit advantage.
Language needs can be met for clinical assessment and therapy.
Emergency transfer procedures and transportation are defined.
A realistic aftercare plan can connect the patient back to providers in the United States.

International placement should not be used to bypass a necessary level of medical care or to solve an acute crisis through travel.

WHEN TO STABILIZE LOCALLY BEFORE REFERRAL

Certain presentations warrant local assessment or stabilization before travel is considered. Examples can include severe alcohol or sedative withdrawal risk, uncontrolled medical illness, active suicidality, psychosis, severe intoxication, unstable pregnancy-related concerns, or any condition requiring immediate hospital capability.

The threshold should be based on the patient’s condition and the receiving facility’s capabilities. A residential center may be appropriate after stabilization even when it is not the correct setting for the acute phase.

Referring clinicians should communicate openly with the receiving medical or admissions team about recent use, withdrawal history, seizures or delirium tremens, overdose history, current vital or laboratory concerns when relevant, psychiatric risk, and medications before travel is approved.

HOW TO EVALUATE THE RECEIVING PROGRAM

SAMHSA’s quality-treatment guidance emphasizes licensing or accreditation, evidence-based practices, family involvement when appropriate, medication treatment when indicated, and attention to broader medical and social needs. Those same quality questions should be applied to an international program, with additional verification of the local regulatory framework.

Licensing and accreditation:

Ask which governmental authority licenses the program and whether it holds independent accreditation. Determine what the accreditation covers and how it can be verified.

Medical and withdrawal-management capability:

Clarify whether physicians and nurses are on site, what withdrawal syndromes the facility manages, what monitoring is available, and what conditions require transfer to a hospital or another level of care.

Psychiatric and co-occurring care:

Confirm access to psychiatric evaluation, medication management, and integrated treatment for co-occurring mental health conditions relevant to the patient.

Language access:

Do not assume that an international facility is clinically bilingual because its admissions team speaks English. Verify whether assessments, individual therapy, group therapy, medical consultations, informed-consent discussions, and written materials are available in the patient’s language.

Medication continuity:

Review current medications before travel and determine whether they can be continued, substituted, or safely managed at the destination. Controlled medications may involve additional travel or regulatory requirements.

Emergency capability:

Ask what happens if the patient deteriorates medically or psychiatrically, which hospital receives transfers, how transportation is arranged, and how the referring clinician or family is notified when authorized.

WHAT INFORMATION SUPPORTS A SAFE HANDOFF

A concise clinical packet can materially improve the receiving team’s ability to prepare for admission. The exact record set should be individualized and shared in accordance with applicable privacy requirements.

High-value information often includes:

Current substances used, route, frequency, quantity when known, and date/time of last use.
History of withdrawal complications, including seizures, delirium, severe autonomic symptoms, or prior medically managed detoxification.
Overdose history and naloxone use when relevant.
Current medication list, doses, prescribing clinicians, allergies, and recent medication changes.
Major medical diagnoses and relevant recent laboratory or diagnostic information.
Psychiatric diagnoses, current symptoms, suicide or self-harm risk history, and recent psychiatric hospitalization when relevant.
Prior addiction-treatment episodes and response to treatment.
Medication treatment for opioid or alcohol use disorder when applicable.
Relevant social, family, housing, occupational, or legal factors that affect discharge planning.
Contact information for the referring clinician and intended U.S. continuing-care providers.

The goal is not to send every record ever created. It is to transfer the information necessary for safe assessment, admission planning, medication continuity, and treatment design.

PRIVACY, HIPAA, AND 42 CFR PART 2

U.S. clinicians should treat privacy and consent as part of the referral workflow rather than an administrative afterthought. HHS explains that HIPAA protects identifiable health information while allowing appropriate uses and disclosures for treatment and other permitted purposes. Substance use disorder records from federally assisted U.S. programs can also be subject to additional confidentiality protections under 42 CFR Part 2.

Because the exact rules depend on the type of provider, record, purpose of disclosure, patient authorization, state law, and organizational status, clinicians should follow their compliance process rather than rely on a generic cross-border rule.

A practical approach is to obtain and document the patient’s informed permission for the referral and record transfer when required, confirm the receiving facility and contact information, use secure transmission methods, and send only information relevant to the treatment transition.

The receiving international provider may operate under a different privacy framework from U.S. HIPAA and Part 2. The referring clinician should explain this distinction to the patient as appropriate and ask the receiving facility how records are protected, who can access them, and how information will be returned to U.S. providers at discharge.

THE VALUE OF A WARM CLINICAL HANDOFF

A referral is stronger when it is clinician-to-clinician rather than simply patient-to-phone-number. A brief handoff can clarify the reason for residential placement, recent risk, medication concerns, prior treatment response, and what the referring clinician hopes will happen next.

When possible, the referring clinician should know who at the receiving program has accepted the case and what information has been reviewed. The receiving program should know how to reach the referring or continuing-care team if new questions arise.

For patients with complex psychiatric or medical comorbidity, a direct discussion between physicians or other appropriate clinicians may be especially useful before travel.

PLAN THE RETURN TO U.S. CARE BEFORE ADMISSION

Cross-border treatment creates a predictable transition point: the patient will eventually return to a different healthcare system. Planning for that transition should begin before or early in residential care.

A strong discharge handoff may include a treatment summary, diagnoses addressed, medication list and changes, relevant clinical findings, relapse-prevention plan, ongoing medication recommendations, and specific aftercare recommendations. When appropriate and authorized, the receiving program can coordinate directly with the U.S. therapist, psychiatrist, primary care clinician, intensive outpatient program, or other follow-up provider.

The most useful endpoint is not simply “follow up after discharge.” It is a named provider, confirmed appointment, medication continuity plan, and crisis or relapse response plan whenever possible.

TRAVEL AND LOGISTICS ARE CLINICAL VARIABLES

For international referrals, travel is not purely administrative. The patient must be stable enough to complete the trip, carry necessary medications and documentation, navigate the arrival process, and reach the facility safely.

Before travel, the patient and receiving program should confirm identification and entry requirements, medication documentation, arrival airport, ground transportation, emergency contacts, and the plan if the patient does not arrive as expected.

Travel advisories can change. For referrals to Mexico, clinicians and patients should review current U.S. Department of State guidance and discuss destination-specific transportation and security procedures with the receiving facility.

REFERRING A PATIENT TO OCEÁNICA

Oceánica is a CARF-accredited residential treatment center in Mazatlán, Mexico. The site serves patients from Mexico, the United States, and other parts of North America and provides residential treatment for substance use and selected mental health conditions.

For professional referrals, Oceánica’s team can discuss admissions criteria, clinical capabilities, current program options, medication and detox considerations, travel logistics, and aftercare coordination. Relevant medical and psychiatric records can support pre-admission review, although the specific information requested depends on the case.

English-speaking clinical support is available for U.S. patients, with bilingual support throughout the program; however, not every staff member is bilingual. Referring clinicians should identify any language requirement explicitly during the referral process.

When the patient is appropriate for admission, the goal is a coordinated handoff into residential care and a coordinated transition back to U.S.-based services. Healthcare professionals can contact Oceánica at (213) 527-3377 to discuss a potential referral confidentially.

REFERRAL CHECKLIST FOR U.S. HEALTHCARE PROFESSIONALS

Confirm the patient’s current level-of-care need and medical stability.
Verify the receiving program’s licensing, accreditation, staffing, and clinical capabilities.
Discuss the case with the receiving admissions or clinical team before travel.
Clarify detox, psychiatric, medication, and emergency-transfer capabilities.
Address language access for clinical care, not only admissions.
Follow HIPAA, 42 CFR Part 2 when applicable, state law, and organizational privacy procedures.
Obtain and document patient authorization or consent as required.
Transfer a concise, clinically relevant record set securely.
Confirm travel, medication documentation, and arrival transportation.
Plan discharge records, medication continuity, and U.S. follow-up before the patient returns home.

FREQUENTLY ASKED QUESTIONS

Can a U.S. healthcare professional refer a patient to addiction treatment in Mexico?

Yes, an international referral can be considered when it is clinically appropriate and the receiving program can meet the patient’s needs. The referring professional should follow applicable licensing, privacy, organizational, and documentation requirements.

What should I verify before referring to an international rehab?

Verify licensing and accreditation, level-of-care capability, withdrawal management, medical and psychiatric staffing, medication policies, language access, emergency transfer procedures, patient rights, travel logistics, and aftercare coordination.

What records should be sent with an international addiction treatment referral?

Useful information often includes current substance use, last use, withdrawal and overdose history, medication list, allergies, relevant medical and psychiatric history, prior treatment, current risk, and contact information for referring and continuing-care providers. Share records in accordance with applicable privacy rules.

Does HIPAA apply when sending records to a foreign treatment center?

U.S. providers remain responsible for complying with HIPAA when it applies to them and should also consider 42 CFR Part 2 for covered substance use disorder records. The receiving foreign provider may operate under a different privacy framework. Use your organization’s compliance process for case-specific guidance.

Should a patient detox before traveling internationally for rehab?

It depends on the patient’s withdrawal risk and the receiving facility’s medical capabilities. Patients with acute instability or a need for a higher level of withdrawal management may require local stabilization before travel.

How should aftercare be coordinated after international rehab?

Ideally, the residential program and U.S. continuing-care team coordinate before discharge. A treatment summary, current medication list, aftercare recommendations, confirmed follow-up appointments, and a crisis or relapse plan support continuity across the transition.

EXTERNAL REFERENCE LINKS

Oceánica is a CARF-accredited residential treatment center in Mazatlán, Mexico. International referrals should be based on clinical fit, patient consent, safe information transfer, travel feasibility, and continuity of care. This article is informational and is not legal, regulatory, or patient-specific medical advice. Healthcare professionals can call (213) 527-3377 or visit oceanica-usa.com.